Lewis Karen's Form 4 filing
Apellis Pharmaceuticals, Inc. (APLS) · filed Apr 5, 2023
- Accession no.
- 0001127602-23-012595
- Filed
- Apr 5, 2023
- Trade date
- Apr 3, 2023
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $375.0K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Lewis KarenCIK 0001814304 | Officer (Chief People Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Apr 3, 2023 | Common Stock | MOption exerciseAcquired | +5,000 | $34.11 | +$170,550 | 46,430 | Direct | |
| Apr 3, 2023 | Common Stock | SSaleDisposed | −5,000 | $75.00 | −$375,000 | 41,430 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Apr 3, 2023 | Common Stock | MOption exerciseDisposed | −5,000 | $0.00 | $0 | 111,000 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.